Therapeutic potential of mitotic kinesin inhibitors in cancer

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 3, 2008, Pages 253-274

  Matsuno, Kenji ^a   Sawada, Jun Ichi ^a   Asai, Akira ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antimitotic; Cancer; CENP E; Centromere associated protein E; Eg5; Inhibitor; Kinesin spindle protein; KSP; Mitotic kinesin

Indexed keywords

1,2,4 OXADIAZIN 5(6H) ONE; 1,2,4 OXADIAZOL 5 ONE; 4H PYRANO[2,3 B]PYRIDINE 4 ONE; 5 OXOHEXAHYDROPYRANO[4,3 D]PYRIMIDIN 2 THIONE; 5 OXOHEXAHYDROPYRIDO[4,3 D]PYRIMIDIN 2 THIONE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ARRY 520; CENTROMERE PROTEIN E; EMD 534085; ENASTRON; GSK 923295; IMIDAZOLIN 2 ONE; ISOQUINOLIN 1 ONE; ISOXAZOLO[4,5 D]PYRIMIDINE DERIVATIVE; ISPINESIB; KINESIN; KINESIN SPINDLE PROTEIN; MITOTIC KINESIN INHIBITOR; MK 0731; MON 97; MONASTROL; OXAZOLIN 2 ONE; PROTEIN INHIBITOR; PYRIDO[1,2 A]PYRIMIDIN 4 ONE; SB 743921; TETRAHYDROPYRIDO[1,2 A]PYRIMIDIN 4 ONE; THIENO[3,2 D]PYRIMIDIN 4 ONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VS 83;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENANTIOMER; ENZYME INHIBITION; FATIGUE; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATENT; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSAMINITIS;

EID: 42549100037     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.3.253     Document Type: Review

References (186)

1. Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 2005;15:467-76
2. Dagenbach EM, Endow SA. A new kinesin tree. J Cell Sci 2004;117:3-7
3. Wittmann T, Hyman A, Desai A. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 2001;3:E28-34
4. Heald R. Motor function in the mitotic spindle. Cell 2000;102:399-402
5. Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41-7
6. Belmont LD. Mitotic kinesins as targets for anticancer therapy. AACR Educ Book 2005;173-7
7. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Update 2007;10:162-81
8. Sawin KE, Leguellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992;359:540-3
9. Kashina AS, Baskin RJ, Cole DG, et al. A bipolar kinesin. Nature 1996;379:270-2
10. Blangy A, Lane HA, D'Herin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69
11. Kapitein LC, Peterman EJ, Kwok BH, et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435:114-8
12. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59
13. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12
14. Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689-98
15. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88
16. Yen TJ, Compton DA, Wise D, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 1991;10:1245-54
17. Yen TJ, Li G, Schaar BT, et al. CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 1992;359:536-9
18. Wood KW, Sakowicz R, Goldstein LS, Cleveland DW. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 1997;91:357-66
19. Thrower DA, Jordan MA, Wilson L. Modulation of CENP-E organization at kinetochores by spindle microtubule attachment. Cell Motil Cytoskel 1996;35:121-33
20. Deluca JG, Newton CN, Himes RH, et al. Purification and characterization of native conventional kinesin, HSET, and CENP-E from mitotic HeLa cells. J Biol Chem 2001;276:28014-21
21. Garcia-Saez I, Yen T, Wade RH, Kozielski F. Crystal structure of the motor domain of the human kinetochore protein CENP-E. J Mol Biol 2004;340:1107-16
22. Neumann I, Garcia-Saez S, Debonis R, et al. Human kinetochore-associated kinesin CENP-E visualized at 17 Å resolution bound to microtubules. J Mol Biol 2006;362:203-11
23. Brown KD, Wood KW, Cleveland DW. The kinesin-like protein CENP-E is kinetochoreassociated throughout poleward chromosome segregation during anaphase-A. J Cell Sci 1996;109:961-9
24. Yao X, Abrieu A, Zheng Y, et al. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2000;2:484-91
25. Putkey FR, Cramer T, Morphew MK, et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 2002;3:351-65
26. Abrieu A, Kahana JA, Wood KW, Cleveland DW. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell 2000;102:817-26
27. Mao Y, Abrieu A, Cleveland DW. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell 2003;114:87-98
28. Tanudji M, Shoemaker J, L'Italien L, et al. Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell 2004;15:3771-81
29. Mayer TU, Kapoor TM, Haggarty SJ, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4
30. Yan Y, Sardana V, Xu B, et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 2004;335:547-54
31. Debonis S, Simorre J-P, Crevel I, et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003;42:338-49
32. Maliga Z, Kapoor TM, Mitchison TJ. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol 2002;9:989-96
33. Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005;5:127-45
34. Duhl DM, Renhowe PA. Inhibitors of kinesin motor proteins: research and clinical progress. Curr Opin Drug Discov Dev 2005;8:431-6
35. Hotta K, Ueoka H. New cytotoxic agents: a review of the literature. Crit Rev Oncol Hematol 2005;55:45-65
36. Zhang B, Senator D, Wilson CJ, Ng SC. Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening. Anal Biochem 2005;345:326-35
37. Davis DA, Sarkar SH, Hussain M, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006;6:22-32
38. Chu Q, Holen KD, Rowinsky EK, et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 2003;22:[Abstract 525]
39. Rodon J, Till E, Patnaik A, et al. Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer 2006;4:[Abstract 640]
40. Tang P, Siu LL, Chen EX, et al. A phase II study of ispinesib in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC). Ann Oncol 2006;17(S):[Abstract 600P]
41. Jackson JR, Gilmartin A, Dhanak D, et al. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. First Mol Diagn Cancer Ther Dev 2006;[Abstract B11]
42. Belmont LD, Wood KW, Sutton D, et al. Sequence dependent anti-tumor activity of bortezomib and the KSP inhibitor, SB743921, in a solid tumor xenograft model. Eur J Cancer 2006;4:[Abstract 378]
43. Holen KD, Belani CP, Wilding G, et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J Clin Oncol 2006;24:[Abstract 2000]
44. A Phase I-II study to determine the safety and pharmacokinetics of intravenous administration of SB-743921 on days 1 and 15 of a 28 day cycle in patients with non-Hodgkin's lymphoma (NCT00343564). ChnicalTrials.gov. 21 June 2006. Available at: http://clinicaltrials.gov/ show/NCT00343564 [Last accessed 14 November 2007]
45. Stein MN, Rubin EH, Scott PD, et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J Clin Oncol 2006;24:[Abstract 2001]
46. Stein MN, Tan A, Taber K, et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors. J Clin Oncol 2007;25:[Abstract 2548]
47. A study of MK0731 in patients with advanced solid tumors (NCT104364). 25 February 2005. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00104364?term=MK0731&rank=1 [Last accessed 14 November 2007]
48. Array BioPharma reports full-year 2007 R&D highlights. Array Biopharma. press release. 6 August 2007. ClinicalTrials.gov. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p= irol-newsArticle&[D=1037137&highlight [Last accessed 14 November 2007]
49. Tolerability study of investigational agent, ARRY-520, in subjects with cancer (NCT00462358). 18 April 2007. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00462358?term=ARRY-520&rank=1 [Last accessed 14 November 2007]
50. Merck KGaA reports Q3 2007 R&D highlights. Merck KGaA press release. 24 October 2007. Available at: http://www.merck.de/servlet/PB/show/ 1755050/Merck_Q3_2007_handout_portfolio_review.pdf [Last accessed 14 November 2007]
51. Lad L, Luo L, Wood K, et al. Detailed biochemical analysis of the CENP-E inhibitor GSK923295A. Proc Am Assoc Cancer Res 2007;48:[Abstract 3179]
52. Sutton D, Diamond M, Faucette L, et al. GSK923295A, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice. Proc Am Assoc Cancer Res 2007;48:[Abstract 1522]
53. Phase I study to assess the safety, pharmacokinetics & pharmacodynamics of GSK923295 in subjects with refractory cancer (NCT00504790). ClinicalTrials.gov. 18 July 2007. Available at: http://clinicaltrials.gov/ct2/show/NCT00504790?term=GSK923295&rank=1 [Last accessed 14 November 2007]
54. Coleman PJ, Fraley ME. Inhibitors of the mitotic kinesin spindle protein. Expert Opin Ther Patents 2004;14:1659-67
55. Jiang C, You Q, Li Z, Guo Q. Kinesin spindle protein inhibitors as anticancer agents. Expert Opin Ther Patents 2006;16:1517-32
56. Commissariat Á L'énergie Atomique. WO2006097617; 2006
57. Garcia-Saez I, Debonis S, Lopez R, et al. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. J Biol Chem 2007;282:9740-7
58. Leipzig University/Max-Planck Institute. WO2006048308; 2006
59. Gartner M, Sunder-Plassmann N, Seiler J, et al. Development and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5. Chem Biochem 2005;6:1173-7
60. Sarli V, Huemmer S, Sunder-Plassmann N, et al. Synthesis and biological evaluation of novel Eg5 inhibitors. Chem Biochem 2005;6:2005-13
61. Harvard University. WO2006074293; 2006
62. Biginelli P. Ueber aldehyduramide des acetessigäthers. Ber 1891;24:1317-9
63. Dondoni A, Massi A, Sabbatini S. Improved synthesis and preparative scale resolution of racemic monastrol. Tetrahedron Lett 2002;43:5913-6
64. Huang Y, Yang F, Zhu C. Highly enantioseletive Biginelli reaction using a new chiral ytterbium catalyst: asymmetric synthesis of dihydropyrimidines. J Am Chem Soc 2005;127:16386-7
65. Chen XH, Xu XY, Liu H, et al. Highly enantioselective organocatalytic Biginelli reaction. J Am Chem Soc 2006;128:14802-3
66. Klein E, Debonis S, Thiede B, et al. New chemical tools for investigating human mitotic kinesin Eg5. Bioorg Med Chem 2007;15:6474-88
67. Cytokinetics. WO2004100873; 2004
68. Cytokinetics. WO2004103282; 2004
69. Cytokinetics. WO2005013888; 2005
70. Cytokinetics. WO2004091547; 2004
71. Cytokinetics. WO2005061460; 2005
72. Cytokinetics. WO2005042697; 2005
73. Cytokinetics. WO2007067752; 2007
74. Chiron. WO2004111058; 2004
75. Chiron. WO2004113335; 2004
76. Chiron. WO2005100357; 2005
77. Cytokinetics. WO2004064741; 2004
78. Chiron. WO2006002236; 2006
79. Chiron. WO2006049835; 2006
80. Takeda WO2006060737; 2006
81. AstraZeneca. WO2006018627; 2006
82. AstraZeneca. WO2006008523; 2006
83. AstraZeneca. WO2006018628; 2006
84. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80
85. Merck KGaA. WO2006097176; 2006
86. BMS. WO2004106492; 2004
87. AstraZeneca. WO2004078758; 2004
88. BMS. WO2005077920; 2005
89. BMS. WO2003099286; 2003
90. Kim KS, Lu S-F, Cornelius LA, et al. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorg Med Chem Lett 2006;16:3937-42
91. Merck & Co. WO2005061518; 2005
92. Merck & Co. WO2006078598; 2006
93. Merck & Co. WO2006078575; 2006
94. Merck & Co. WO2006078574; 2006
95. AstraZeneca. WO2005041888; 2005
96. Cytokinetics. WO2004009036; 2004
97. Cytokinetics/GSK. WO2004055008; 2004
98. Merck & Co. WO2003039460; 2003
99. Merck KGaA. WO2006125555; 2006
100. Chiron. WO2005051922; 2005
101. Chiron. WO2007021794; 2007
102. Cox CD, Breslin MJ, Mariano BJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2005;15:2041-5
103. Fraley ME, Garbaccio RM, Arrington KL, et al. Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2006;16:1775-9
104. Garbaccio RM, Fraley ME, Tasber ES, et al. Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorg Med Chem Lett 2006;16:1780-3
105. Cox CD, Torrent M, Breslin MJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 4: structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2006;16:3175-9
106. Cox CD, Breslin MJ, Whitman DB, et al. Kinesin spindle protein (KSP) inhibitors. Part 5: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein. Bioorg Med Chem Lett 2007;17:2697-702
107. Coleman PJ, Schreier JD, Cox CD, et al. Kinesin spindle protein (KSP) inhibitors. Part 6:design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5390-5
108. Merck & Co. WO2006110390; 2006
109. Merck & Co. WO2006101761; 2006
110. Merck & Co. WO2006007496; 2006
111. Merck & Co. WO2005017190; 2005
112. Merck & Co. WO2005019205; 2005
113. Merck & Co. WO2005019206; 2005
114. Merck & Co. WO2006101780; 2006
115. Merck & Co. WO2005018547; 2005
116. Merck & Co. WO2006007501; 2006
117. Kyowa Hakko/Fuji Film. WO2005035512; 2005
118. Kyowa Hakko/Fuji Film. JP2005232016; 2005
119. Merck & Co. WO2006031348; 2006
120. Array Biopharma. WO2006044825; 2006
121. Merck & Co. WO2006023440; 2006
122. Merck & Co. WO2004112699; 2004
123. Merck & Co. WO2005018638; 2005
124. Merck & Co. WO2006086358; 2006
125. Merck & Co. WO2006007491; 2006
126. Merck & Co. WO2006023083; 2006
127. Garbaccio RM, Tasber ES, Neilson LA, et al. Kinesin spindle protein (KSP) inhibitors. Part 7: design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5671-6
128. Roecker AJ, Coleman PJ, Mercer SP, et al. Kinesin spindle protein (KSP) inhibitors. Part 8: design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5677-82
129. Merck & Co. WO2006068933; 2006
130. Merck & Co. WO2004111193; 2004
131. Merck & Co. WO2006007497; 2006
132. Tarby CM, Kaltenbach III RF, Huynh T, et al. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorg Med Chem Lett 2006;16:2095-100
133. GSK/Cytokinetics. WO2005060692; 2005
134. GSK. WO2005062847; 2005
135. GSK/Cytokinetics. WO2006020358; 2006
136. Parrish CA, Adams ND, Auger KR, et al. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 2007;50:4939-52
137. Jackson JR, Auger KR, Gilmartin AG, et al. A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site. Mol Targets Cancer Ther 2005:[Abstrart C207]
138. GSK. WO2006113432; 2006
139. Merck KGaA. WO2005063735; 2005
140. Merck KGaA. WO2007054138; 2007
141. Merck KGaA. WO2006133805; 2006
142. Merck KGaA. WO2006002726; 2006
143. Merck KGaA. WO2006133821; 2006
144. Altana. WO2006018435; 2006
145. Nycomed. WO2007096393; 2007
146. Nycomed. WO2007096395; 2007
147. Chiron. WO2005070930; 2005
148. Schering. WO2006098961; 2006
149. Schering. WO2006098962; 2006
150. Kalypsys. WO2007011721; 2007
151. Kalypsys. WO2007011760; 2007
152. Kalypsys. WO2007011759; 2007
153. Kalypsys. WO2007011647; 2007
154. Pinkerton AB, Lee TT, Hoffman TZ, et al. Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors. Bioorg Med Chem Lett 2007;17:3562-9
155. Ogo N, Oishi S, Matsuno K, et al. Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors. Bioorg Med Chem Lett 2007;17:3921-4
156. Skoufias DA, Debonis S, Saoudi Y, et al. S-Trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 2006;281:17559-69
157. Merck KGaA. WO2006094602; 2006
158. Okumura H, Nakazawa J, Tsuganezawa K, et al. Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells. Toxicol Lett 2006;166:44-52
159. Riken. JP2006348021; 2006
160. Cytokinetics. WO2002057244; 2002
161. Merck & Co. WO2004004652; 2004
162. Liu F, You Q, Chen Y. Pharmacophore identification of KSP inhibitors. Bioorg Med Chem Lett 2007;17:722-6
163. Jiang C, Chen Y, Wang X, You Q. Docking studies on kinesin spindle protein inhibitors: an important cooperative 'minor binding pocket' which increases the binding affinity significantly. J Mol Model 2007;13:987-92
164. Cytokinetics. WO2005107762; 2005
165. Cytokinetics. WO2007056056; 2007
166. Cytokinetics. WO2007056143; 2007
167. Cytokinetics. WO2007056078; 2007
168. Johnson RK, Mccabe FL, Caulder E, et al. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002;43:[Abstract 1335]
169. Chu QS, Holen KD, Rowinsky EK, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Am Soc Clin Oncol 2004;23:[Abstract 2078]
170. Williams D, Kathman S, Chu Q, et al. A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/ pharmacodynamic (PD) modelling of absolute neutrophil counts (ANC). Eur J Cancer Suppl 2004;2:[Abstract 55]
171. Burris HA, Lorusso P, Jones S, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Proc Am Soc Clin Oncol 2004;23:[Abstract 2004]
172. Study of ispinesib in subjects with breast cancer (NCT00089973). ClinicalTrials.gov. 18 August 2004. Available at http://clinicaltrials.gov/ct2/show/NCT00089973?id=NCT00089973&rank= 1 [Last accessed 14 November 2007]
173. Ispinesib in subjects with ptatinum-taxanerefractory or resistant relapsed ovarian cancer (NCT00097409). ClinicalTrials.gov. 23 November 2004. Available at http://clinicaltrials.gov/ct2/show/ NCT00097409?id=NCT00097409&rank=1 [Last accessed 14 November 2007]
174. Ispinesib in patients with advanced or metastatic non-small cell lung cancer (NCT00085813). CtinicalTrials.gov. 14 June 2004. Available at: accessed] http://clinicaltrials.gov/ct2/show/ NCT00085813?id=NCT00085813&rank=1 [Last accessed 14 November 2007]
175. SB-715992 in treating patients with recurrent or metastatic head and neck cancer (NCT00095628). ClinicalTrials.gov. 5 November 2004. Available at http://clinicaltrials.gov/ct2/show/ NCT00095628?id=NCT00095628&rank=1 [Last accessed 14 November 2007]
176. SB-715992 in treating patients with acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes (NCT00098826). ClinicalTrials.gov. 8 December 2004. Available at http://clinicaltrials.gov/ct2/show/NCT00098826?id=NCT00098826&rank=1 [Last accessed 14 November 2007]
177. Lee CW, Bélanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2007; published online 26 October 2007, doi:10.1007/ s10637-007-9097-9
178. Cytokinetics announces the initiation of Phase I/II clinical trial for SB-743921. Cytokinetics press release. 17 April 2006. Available at http://www.cytokinetics.com/cyto/pr_1145284422 [Last accessed 14 November 2007]
179. Woessner RD, Corrette C, Allen S, et al. ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Proc Am Assoc Cancer Res 2007;48:[Abstract 1433]
180. Lemieux C, Dewolf W, Voegtli W, et al. ARRY-520, a novel, highly selective KSP inhibitor with potent anti-proliferative activity. Proc Am Assoc Cancer Res 2007;48:[Abstract 5590]
181. GARBER K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst 2005;97:874-6
182. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells.) J Biol Chem 2005;280:11569-77
183. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88
184. Aoki S, Ohta K, Yamazaki T, et al. Mammalian mitotic centromere-associated kinesin (MCAK). FEBS J 2005;272:2132-40
185. Cytokinetics. WO2004026226; 2004
186. Max-Planck Institute. WO2006079478; 2006